The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in income, its patent expiration created a wave of lower-priced alternatives , significantly diminishing its position . While certain firms may attempt to capitalize on male sexual dysfunction, the current